Hims & Hers
Hims & Hers is a direct-to-consumer telehealth platform offering online consultations and prescription delivery for hair loss, erectile dysfunction, skincare, mental health, and weight loss treatments. The platform connects patients with licensed healthcare providers through asynchronous messaging and video visits, primarily targeting younger adults seeking convenient, stigma-free access to common health conditions.
Score generated by AI agents based on publicly cited evidence and reviewed by the project maintainer. Not independently validated.
Score History
Timeline events are AI-curated from public reporting. Score trajectory is derived from documented events.
Hims launched as a straightforward direct-to-consumer telehealth startup focused on destigmatizing men's health. The platform offered hair loss and ED treatments through a clean subscription model with transparent pricing. With $7 million in seed funding and no complex regulatory arbitrage, the company's enshittification footprint was minimal across all dimensions.
The SPAC merger with Oaktree at a $1.6 billion valuation introduced public-market growth expectations. Aggressive marketing spending reached 48-51% of revenue, and the Apostrophe acquisition for $190 million signaled acquisition-driven growth. Subscription auto-renewal practices began generating consumer complaints, and the Hers brand expansion doubled the addressable market. The company was still primarily a telehealth subscription service without the regulatory arbitrage that later defined it.
Marketing spending consumed 46-51% of revenue as the company scaled aggressively. The STAT/Markup investigation revealed Hims was sharing patient health data with Big Tech advertising platforms via tracking pixels. BBB complaints accumulated as subscription cancellation friction increased. Revenue grew 65% in 2023 to $872 million, but the growth-at-all-costs approach began eroding consumer trust and attracting regulatory attention.
Hims pivoted heavily into compounded semaglutide, exploiting the FDA drug shortage loophole to sell GLP-1 weight loss drugs at a fraction of branded prices. The MedisourceRx acquisition vertically integrated manufacturing. GLP-1 revenue hit $200 million for 2024, driving 69% total revenue growth to $1.48 billion. However, the regulatory gamble built the company's fastest-growing business on a legal foundation that the FDA was actively working to close, while subscription dark patterns continued deepening.
Hims & Hers faces simultaneous enforcement from the FDA (warning letters, compounding ban), FTC (cancellation practices probe), DOJ (federal law violations referral), SEC (investor disclosure investigation), and Novo Nordisk (patent infringement lawsuit). CEO Dudum sold over $46 million in stock during 2025 while the company laid off 4% of workers. The $190 million Apostrophe acquisition was written off and shut down. The company spent $10+ million on a second Super Bowl ad while under active investigation by four federal agencies.
Alternatives
The closest direct competitor for DTC telehealth covering ED, hair loss, weight management, and skincare — same convenient model without the FTC investigation into cancellation practices or FDA warning letters for deceptive marketing. Switching is easy: cancel Hims, sign up with Ro, and restart your care consultation. Ro has its own subscription model so read the cancellation terms carefully before committing.
Broader telehealth platform (score 47, Actively Enshittifying — 5 points better) that covers primary care, mental health, dermatology, and chronic conditions. Works with most insurance plans, which Hims & Hers generally does not. Less specialized for conditions like ED or hair loss, but a more transparent service model without the auto-renewal dark patterns Hims is under FTC investigation for.
Dimensional Breakdown
Summaries below were written by AI agents based on the cited evidence. They are editorial interpretations, not independent research findings.
Dimension History
Timeline (38 events)
Hims Launches DTC Men's Telehealth Platform
Andrew Dudum, Jack Abraham, Joe Spector, and Hilary Coles founded Hims as a direct-to-consumer telehealth startup focused on men's health, initially offering treatments for hair loss and erectile dysfunction. The company secured $7 million in seed funding and launched with a destigmatization-focused brand targeting younger men.
Hers Brand Expands Platform to Women's Health
Exactly one year after launching Hims, the company introduced the Hers brand targeting women's health, offering birth control, Addyi for sexual wellness, skincare, and hair loss treatments. Prices ranged from $15 to $75 per month. The expansion doubled the addressable market.
Early Auto-Renewal Complaints Surface on BBB
As Hims' subscriber base grew past its initial launch phase, consumer complaints about auto-renewal practices began appearing on the BBB and ConsumerAffairs. Users reported being charged for subscription renewals they did not expect, with the company's no-refund policy for processed medication orders creating friction for those who missed the cancellation window. These early complaints established patterns that would later draw FTC scrutiny.
COVID-Driven Mental Health Services Launch
Hims launched mental health services with free anonymous group therapy sessions covering COVID-19 coping, anxiety management, and relationship advice. Later expanded to one-on-one psychiatric evaluations at $59 per visit and $50/month ongoing service. The pandemic accelerated telehealth adoption as one-third of Americans showed signs of clinical anxiety or depression.
Hims & Hers Goes Public via SPAC Merger
Hims & Hers completed its merger with Oaktree Acquisition Corp., valuing the company at $1.6 billion. The deal generated $279.5 million in proceeds, with $204.5 million from the SPAC trust and $75 million from private investors including Franklin Templeton. Management rolled 90-100% of their equity into the combined entity, and shares began trading on NYSE under HIMS.
Apostrophe Acquisition for $190 Million
Hims & Hers acquired teledermatology platform Apostrophe for $190 million, gaining a vertically integrated mail-order pharmacy licensed in 29 states and a board-certified dermatology network. The deal was positioned as accelerating scale in skincare. Apostrophe was later shut down in March 2025 as the company pivoted to weight loss.
Marketing Spend Doubles to $272 Million in 2022
Hims & Hers' marketing expense reached $272.6 million in 2022, a 100.6% year-over-year increase, representing approximately 52% of the company's $526.9 million revenue. The spending included $3 million per week on social and video ads, with professionally produced TV-style campaigns driving subscriber growth to over 1 million -- an 88% year-over-year increase. The aggressive spend-to-grow ratio signaled prioritization of subscriber acquisition over profitability.
Subscription Lock-in Deepens with Multi-Month Plans
Hims & Hers expanded its subscription model to emphasize quarterly and annual plans with lower per-month pricing, creating lock-in through prepayment commitments. Patients on longer-term plans faced the 48-hour advance cancellation window plus forfeiture of prepaid months. Medical records accumulated on the platform were not easily portable to competing telehealth services, adding therapeutic switching costs on top of financial ones.
Investigation Reveals Health Data Shared with Big Tech
A joint STAT/The Markup investigation found that Hims & Hers was among 49 telehealth companies whose websites shared sensitive patient data with Meta, Google, TikTok, and other advertising platforms via tracking pixels. Data shared included medication cart additions, checkout events, and answers to medical intake questionnaires regarding health conditions and drug use.
BBB Complaints Surge Past 300 as Service Quality Declines
By mid-2023, BBB complaints against Hims & Hers surpassed 300, with users citing incorrect billing, unauthorized charges, contradictory support responses, and medications arriving late. ConsumerAffairs reviews documented patterns of copy-paste customer service replies and inconsistent provider quality across consultations, as the company prioritized rapid subscriber growth over service infrastructure.
FTC Opens Formal Investigation into Cancellation Practices
The FTC demanded information from Hims & Hers in October 2023, formally opening an investigation into whether the company's subscription cancellation practices violated the Restore Online Shoppers' Confidence Act (ROSCA). The probe examined cancellation flows, disclosure language, and whether marketing crossed legal lines. Hims acknowledged 'voluntarily cooperating' but declined to share details about the scope.
Marketing Spend Hits 51% of Revenue as Growth Prioritized
Hims & Hers spent $116.1 million on marketing in Q3 2023 alone, representing 51% of quarterly revenue of $226.7 million. Annual marketing expense for 2023 continued the aggressive spending pattern, with the company spending roughly half of every dollar earned on customer acquisition. Revenue grew 65% to $872 million, but the spend ratio raised questions about sustainable unit economics.
Glassdoor Reviews Document Toxic Workplace Culture
Glassdoor reviews in late 2023 and early 2024 revealed deepening workplace culture problems at Hims & Hers, with ratings at 2.9/5 stars. Employees described 'lack of structure, diversity, and toxic company culture,' with HR 'offering nothing more than empty promises and lip service while harassment continued unchecked.' Workers reported roles 'created out of thin air' with undefined expectations, and career advancement contingent on being 'a favorite with senior leadership' rather than merit.
Pricing Opacity Deepens with Multi-Tier GLP-1 Plans
As Hims prepared to launch compounded semaglutide offerings, it introduced complex multi-tier pricing structures where costs varied significantly by plan duration and treatment type in non-obvious ways. The weight loss program launched with introductory pricing ($49 first month, rising to $199/month for injectables), creating information asymmetry about true long-term costs. Standardized treatment protocols further limited provider discretion in ways patients could not observe.
Compounded Semaglutide Injections Launched at $199/Month
Hims & Hers began offering compounded injectable semaglutide for weight loss at $199/month, exploiting an FDA shortage designation that permitted compounding pharmacies to produce copies of Novo Nordisk's Wegovy. The offering quickly became the company's fastest-growing product line, contributing over $200 million to 2024 revenue.
MedisourceRx Compounding Pharmacy Acquired for $31 Million
Hims & Hers acquired MedisourceRx, a 503B outsourcing facility, for $31 million to vertically integrate drug manufacturing. The acquisition transformed the company from a distributor into a manufacturer of compounded medications. FDA inspections later revealed pest contamination and unreported adverse events at the facility.
Hims Launches $100 Million Stock Buyback Program
Hims & Hers announced its first share repurchase program authorizing up to $100 million in buybacks. The program was completed by November 2025, with CEO Dudum simultaneously conducting $46+ million in personal stock sales during the same period, raising questions about capital allocation priorities.
Amazon Telehealth Entry Crashes Hims Stock 24%
Amazon launched fixed-price telehealth services for hair loss and erectile dysfunction through Amazon One Medical, offering $29 messaging consultations and $49 video visits with same-day prescription delivery for Prime members. Hims & Hers stock fell 24% in its worst single-day decline. Bank of America downgraded to 'underperform,' citing Amazon's 29-42% pricing advantage on Hims' core products.
$1 Million Donation to Trump Inauguration Fund
Hims & Hers donated $1 million to President Trump's inauguration fund, becoming the first digital health company to make such a contribution. The seven-figure donation reportedly came with invitations to 'intimate' dinners with Trump and Vice President Vance. The donation coincided with the company facing escalating FDA scrutiny over its compounded drug business.
Compounded Semaglutide Pill Announced at $49/Month
Hims & Hers announced a once-daily compounded semaglutide pill at $49 for the first month, positioning it as a low-cost alternative to Novo Nordisk's branded Wegovy. Novo Nordisk immediately called it 'an unapproved, inauthentic, and untested knockoff' and vowed to sue. The launch was cancelled the next day after FDA backlash.
HHS Refers Hims to DOJ for Federal Law Violations
HHS General Counsel Mike Stuart referred Hims & Hers to the Department of Justice for potential violations of the Federal Food, Drug, and Cosmetic Act and applicable Title 18 criminal provisions. The referral came one day after the company announced its compounded semaglutide pill, targeting the company's plan to mass-produce copies of Wegovy.
Super Bowl Ad Draws Backlash for Misleading GLP-1 Claims
Hims & Hers aired a 60-second 'Sick of the System' Super Bowl ad promoting compounded semaglutide without disclosing side effects or safety information. Senators Durbin and Marshall warned it 'risks misleading patients.' The Partnership for Safe Medicines called it 'nothing short of reckless.' Novo Nordisk responded with full-page newspaper ads asking 'Do you really know what you're injecting?'
FDA Removes Semaglutide from Drug Shortage List
The FDA removed semaglutide from its shortage list, eliminating the legal basis for compounding pharmacies to produce copies. This was devastating for Hims & Hers, which had built $200 million in annual GLP-1 revenue on the compounding loophole. The company was forced to find alternative strategies for its weight loss business.
Apostrophe Teledermatology Platform Abruptly Shut Down
Hims & Hers shut down Apostrophe, the teledermatology platform it acquired for $190 million in 2021. All subscriptions were cancelled immediately, and customers lost access to provider teams and patient accounts within 30 days. The closure reflected the company's all-in pivot toward weight loss at the expense of its dermatology patient base.
Novo Nordisk Partnership to Sell Branded Wegovy
Hims & Hers announced a partnership with Novo Nordisk to sell branded Wegovy directly to consumers at $599/month. The deal was intended to replace lost compounded semaglutide revenue. However, Hims continued selling compounded versions alongside the branded product, setting the stage for the partnership's collapse.
68 Employees Laid Off Amid GLP-1 Regulatory Disruption
Hims & Hers cut 68 employees, approximately 4% of its 1,600-person workforce, across multiple divisions. The layoffs were linked to the FDA's ban on compounded GLP-1 copies, though the company claimed they were 'unrelated to the regulatory change.' The cuts came while CEO Dudum continued personal stock sales totaling over $46 million in 2025.
Zava European Telehealth Acquisition Announced
Hims & Hers announced plans to acquire Zava, a European telehealth platform operating in the UK, Germany, France, and Ireland, adding 1.3 million customers to the existing 2.4 million subscriber base. The expansion diversified the company geographically as its US compounded drug business faced regulatory collapse.
FDA Warning Letter to MedisourceRx for Manufacturing Violations
The FDA issued a warning letter to MedisourceRx, the Hims-owned compounding pharmacy, citing serious violations including pest contamination (a live spider found in the pharmaceutical ingredient production area, a dead cricket in the drug-filling incubator room) and failure to report a serious adverse event involving a patient hospitalized for three nights after taking compounded semaglutide.
Novo Nordisk Terminates Partnership, Stock Crashes 34.6%
Novo Nordisk terminated its collaboration with Hims & Hers after just eight weeks, publicly accusing the company of 'illegal mass compounding' and 'deceptive marketing that put patient safety at risk.' The stock crashed 34.6% in a single day, falling from $64.22 to $41.98. Novo stated Hims had used the partnership as a 'credibility shield' while continuing illegal practices.
Securities Class Action Lawsuit Filed Against Hims
A class action lawsuit was filed in California's Northern District accusing Hims, CEO Andrew Dudum, and CFO Yemi Okupe of misleading investors who bought stock between May 5 and June 23, 2025. The complaint alleged violations of Sections 10(b) and 20(a) of the Securities Exchange Act, claiming the company misrepresented its GLP-1 business and the Novo Nordisk partnership's viability.
CEO Dudum Sells $33 Million in Largest Insider Trade
CEO Andrew Dudum sold 660,000 shares worth $33 million through a family trust in the company's largest insider transaction since going public. The sale occurred under a pre-scheduled 10b5-1 trading plan adopted in August 2024. Additional sales of $2.5 million in July and $11 million in October 2025 brought Dudum's total 2025 insider sales above $46 million, all while the company faced FTC, FDA, DOJ, and SEC scrutiny.
FTC Probe into Cancellation Practices Revealed
Bloomberg reported that the FTC had been investigating Hims & Hers for over a year, examining whether the company violated the Restore Online Shoppers' Confidence Act (ROSCA) by making subscriptions unreasonably difficult to cancel. The probe focused on cancellation flows, disclosure language, and marketing practices. Hims stock fell on the news, adding to investor concerns from the pending securities class action.
Class Action Investigation into Auto-Renewal Practices
Law firm Ahdoot & Wolfson launched a class action and mass arbitration investigation into Hims & Hers' auto-renewal and cancellation practices. The investigation documented consumers being charged after cancellation attempts, missing cancellation buttons in the interface, and a mandatory 48-hour advance cancellation window combined with a no-refund, no-return policy for processed medication orders.
FDA Issues Warning Letters for Misleading Drug Marketing
The FDA issued formal warning letters to both Hims and Hers entities for misleading marketing of compounded semaglutide products. The FDA found claims were 'false or misleading' under the FDCA, including telling customers that compounded products contained 'the same active ingredient' as Ozempic and Wegovy. The products were declared misbranded drugs introduced into interstate commerce in violation of federal law.
$250 Million Stock Buyback Program Announced
Hims & Hers announced a new $250 million share repurchase program over three years, following the completion of its initial $100 million buyback. CEO Dudum stated the market 'may not fully reflect what we believe is its intrinsic value.' The buyback came while Dudum was simultaneously conducting tens of millions in personal stock sales and the company faced multiple regulatory investigations.
FDA Closes Compounding Loophole on Semaglutide
The FDA took definitive enforcement action against compounded semaglutide, eliminating the regulatory basis for Hims & Hers' weight loss drug business. HHS simultaneously referred Hims to the DOJ for potential violations of the FDCA and criminal provisions under Title 18. The action threatened the company's fastest-growing revenue stream, which had driven $200 million in 2024 revenue.
Second Consecutive Super Bowl Ad Despite Ongoing Controversy
Hims & Hers aired its second consecutive Super Bowl ad, 'Rich People Live Longer,' narrated by Common, positioning itself as an advocate against healthcare inequality. The ad ran while the company faced active FDA warning letters, an FTC investigation, DOJ referral, SEC inquiry, Novo Nordisk patent lawsuit, and securities class action litigation. The estimated cost exceeded $10 million.
Novo Nordisk Files Patent Infringement Lawsuit
Novo Nordisk filed a sweeping patent infringement lawsuit against Hims & Hers, targeting the company's 'personalized' compounding formulations of semaglutide and seeking a permanent ban on Hims selling compounded versions of Wegovy and Ozempic. The lawsuit came three days after the FDA's enforcement action and DOJ referral, intensifying the legal pressure from multiple directions simultaneously.
Evidence (42 citations)
D1: User Value Erosion
D2: Business Customer Exploitation
D3: Shareholder Extraction
D4: Lock-in & Switching Costs
D5: Twiddling & Algorithmic Opacity
D6: Dark Patterns
D7: Advertising & Monetization Pressure
D8: Competitive Conduct
D9: Labor & Governance
D10: Regulatory & Legal Posture
Scoring Log (4 entries)
Added 1 missing dimension narrative
Fixed Ro: url changed to slug (ro exists in slug-lookup)